Using myeloid cell lineages (monocytes, mature macrophages, and granulocytes)‐specific conditionally SHP2 knockout mice (M‐Shp2−/− mice) or a SHP2‐allosteric inhibitor (SHP099), we demonstrated that SHP2 inhibition attenuated the IMQ‐induced psoriasis‐like phenotype, suggesting that SHP2 is a positive regulator of psoriatic disease progression. The gene discussed is PTPN11; the disease is psoriasis.